Epidermolysis bullosa pipeline anticipated to offer several novel pipeline therapies in the next decade

Los Angeles, USA, Jan. 12, 2021 (GLOBE NEWSWIRE) — Epidermolysis bullosa pipeline anticipated to offer several novel pipeline therapies in the next decade 

The Epidermolysis bullosa clinical pipeline comprises 20+ notable therapeutic agents in different stages of clinical development varying from Gene therapies, Cell therapies, RNA‐targeting therapy, Protein therapy, Topical therapies, and Small molecules.

DelveInsight’s Epidermolysis bullosa pipeline report offers comprehensive insights into the present clinical development scenario and growth prospects across the Epidermolysis Bullosa market. The pipeline report lists down the available treatment options in the Epidermolysis bullosa therapeutics market, unmet needs, and comprehensive analysis of upcoming therapies in the pipeline in different stages of the clinical development, major pharmaceutical companies developing the drug, route of administration, molecule type, and product type. 

Epidermolysis bullosa Pipeline Report Research Highlights

• 30+ key companies are working to strengthen the Epidermolysis bullosa pipeline including Takeda, TWi Biotechnology, Inc., Krystal Biotech, and several others. 
• Pipeline therapies in different stages of clinical development FCX-007 (debcoemagene autoficel in Phase III, PTR-01 in Phase II, etc.)
• Collaborations & Partnering deals
• Current Prominent Research Areas and Key Players
• Pipeline product profiles 
• Market Drivers and Barriers

Have a query? Ask our Experts @ Epidermolysis bullosa therapeutics 

Epidermolysis bullosa is a disease that results in a wide spectrum of skin diseases. It is characterized by blister formation in response to mechanical trauma and is complicated by infection, sepsis, and death. The condition worsens with the unavailability of proper diagnostics tools, and lack of awareness. 

At present no approved therapy or cure is available. The current Epidermolysis Bullosa market is mainly based on supportive care; hence new therapies are expected to transform the treatment landscape of Epidermolysis bullosa. 

Know more about the EB pipeline report offerings @ Epidermolysis bullosa emerging therapies 

The primary goal of Epidermolysis bullosa treatment is to guard skin against any frictional trauma and infections. The current Epidermolysis bullosa treatment market is dominated by therapies that offer symptomatic care. Antihistamines, gabapentin, pregabalin, TCA, serotonin-norepinephrine uptake inhibitors (SNRIs), and other nontraditional antipruritic agents for itch treatment, paracetamol and ibuprofen for mild pain while opioids and anxiolytics for severe pain, corticosteroids for easy swallowing of solid foods, nutritional support including dietary supplements, and others. 

However, over the years, EB care has improved dramatically. Several companies are Fibrocell Technologies, Castle Creek Pharmaceuticals, RegeneRx, Amryt Pharma, Abeona Therapeutics, Krystal Biotech, Shionogi, among others are developing therapies for the treatment of EB.

Request for sample for more insights into the emerging therapies, clinical trials, and key companies @ Epidermolysis bullosa pipeline insights

Amryt Pharma is developing Oleogel-S10 (AP-101), a topical product for the treatment of EB, which at the moment is in phase III clinical trial and recently reported positive unblinded interim efficacy and safety analyses. Similarly, Castle Creek Pharmaceuticals is also developing CCP-020 (Diacerein 1% Ointment), a topical ointment for the treatment of Epidermolysis Bullosa Simplex (EBS).

While some are exploring topical ways to address the condition, others are digging deeper with gene therapies. Abeona Therapeutics is experimenting with an autologous, ex-vivo gene therapy EB-101 (LZRSE-Col7A1) for the treatment of the underlying disease in recessive dystrophic epidermolysis bullosa (RDEB). The company has evaluated the safety of EB-101 in phase I/II trial and is planning to move further. Fibrocell is also investigating a clinical-stage gene therapy product FCX-007 for the treatment of RDEB. Fibrocell’s project enrollment and dosing of phase III patients is expected to be completed in the third quarter of 2020. If everything goes as planned, Fibrocell plans to file a Biologics License Agreement (BLA) for FCX-007 in 2021.

The present EB market landscape presents quite a promising picture with various ongoing clinical studies. It goes beyond doubt that gene therapies and stem cell therapies have the potential to provide an effective therapeutic approach for the management of EB. Several institutes such as CHOP are also currently involved in EB clinical trials looking at new topical therapies to help promote wound healing. 

Current Treatment Scenario and Emerging Therapies:

• What are the current options for Epidermolysis Bullosa treatment?
• How many companies are developing therapies for the treatment of Epidermolysis Bullosa? 
• What are the principal therapies developed by these companies in the industry?
• How many Epidermolysis Bullosa emerging therapies are in early-stage, mid-stage, and late stages of development for the treatment of Epidermolysis Bullosa?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Epidermolysis Bullosa market? 
• What are the key designations that have been granted for the emerging therapies for Epidermolysis Bullosa? 
• How many patents are granted and pending for the emerging therapies for the treatment of Epidermolysis Bullosa? 

Scope of the report

• Coverage: Global. 
• Key Companies: Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies/Castle Creek Pharmaceuticals, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, Phoenix Tissue Repair (BridgeBio Pharma, Inc), Menlo Therapeutics, and others
• Phases

1. Mid-stage products (Phase II and Phase I/II)
2. Early-stage products (Phase I/II and Phase I) along with the details of
3. Pre-clinical and Discovery stage candidates
4. Discontinued & Inactive candidates

• Therapeutic assessment of the pipeline drugs by the Route of Administration:

• • 1. Intradermal
    2. Topical
    3. Intravenous
    4. In vivo grafting
    5. Ex vivo grafting

• Comprehensive coverage of key companies and their detailed insights into their drug candidates. 
• Major collaborations between pharmaceutical companies and academia. 
• Ongoing clinical trials segmented into different phases. 
• Recent happenings on the research front and news front in the EB market. 

Epidermolysis bullosa Therapeutics

• Oleogel-S10 (AP-101): Amryt Pharma
• EB-101: Abeona Therapeutics
• CCP-020 (Diacerein 1% Ointment): Castle Creek Pharmaceuticals
• RGN-137: RegeneRx
• B-VEC (KB103, Beremagene Geperpavec): Krystal Biotech
• FCX-007: Fibrocell Technologies/Castle Creek Pharmaceuticals
• Allo-APZ2-EB: RHEACELL GmbH
• COL7 and LAMB3 gene therapy: Holostem Terapie Avanzate
• KOI2 (Redasemtide/HMGB1 Peptides): StemRim/Shionogi
• PTR-01 (BBP-589): Phoenix Tissue Repair (BridgeBio Pharma, Inc)
• Serlopitant (VPD-737): Menlo Therapeutics

For further product details, contact @  Epidermolysis bullosa drug pipeline 

Table of Contents 

Related Reports 

Epidermolysis Bullosa Market 

DelveInsight’s ‘Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2030’ report offers a comprehensive and thorough description of the disease, its epidemiological trends, treatment landscape, and market trends, opportunities and constraints in the 7MM ( the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan) for the study period 2017-30.

Dystrophic Epidermolysis Bullosa Market

DelveInsight’s “Dystrophic Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Dystrophic Epidermolysis Bullosa , historical and forecasted epidemiology as well as the Dystrophic Epidermolysis Bullosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recessive Dystrophic Epidermolysis Market

DelveInsight’s “Recessive Dystrophic Epidermolysis Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Recessive Dystrophic Epidermolysis, historical and forecasted epidemiology as well as the Recessive Dystrophic Epidermolysis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recessive Dystrophic Epidermolysis Epidemiology Forecast

DelveInsight’s ‘Recessive Dystrophic Epidermolysis Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Recessive Dystrophic Epidermolysis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Dystrophic Epidermolysis Bullosa Epidemiology Forecast

DelveInsight’s ‘Dystrophic Epidermolysis Bullosa Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Dystrophic Epidermolysis Bullosa epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Epidermolysis Bullosa Epidemiology Forecast

DelveInsight’s ‘Epidermolysis Bullosa Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Epidermolysis Bullosa (EB) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us:

Shruti Thakur 

[email protected] 

+1(919)321-6187 

www.delveinsight.com